Skip to content
tablet in a hand

BioNova Announces 乐舒克® (Belumosudil Mesylate Tablets) Approval by China NMPA for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

BioNova announces 乐舒克® (Belumosudil Mesylate Tablets) has been approved by the China NMPA for the treatment of patients with cGVHD who have an inadequate response to corticosteroids or other systemic treatments.

Back To Top